

# Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

<https://marketpublishers.com/r/IEB3379F1C6EN.html>

Date: December 2017

Pages: 25

Price: US\$ 3,500.00 (Single User License)

ID: IEB3379F1C6EN

## Abstracts

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

### SUMMARY

According to the recently published report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017'; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017' outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based

on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)

The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin

## Alpha 7 (ITGA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 7 (ITGA7) - Overview

Integrin Alpha 7 (ITGA7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 7 (ITGA7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development

Strykagen Corp

Integrin Alpha 7 (ITGA7) - Drug Profiles

Stryka-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress  
Stryka-969 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Stryka-978 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
StrykaPro-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Strykagen Corp, H2 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

### COMPANIES MENTIONED

Strykagen Corp

## I would like to order

Product name: Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/IEB3379F1C6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IEB3379F1C6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970